



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

CAT update September 2018

Kieran Breen
Committee for Advanced Therapies

An agency of the European Union







CAR T cells

- Next generation of immunotherapy for the treatment of cancer
- Generation of genetically-engineered T-lymphocytes (white blood cells) derived from the patient's own blood (autologous) or derived from a healthy person (allogenic)
- Cells genetically modified to express a receptor directed against surface components of tumour cells which directs them to the tumour to kill the cell
- Currently being developed primarily to treat leukaemia and lymphoma although it is likely that this portfolio will expand to treat solid tumours

CAR T cells



CAR T cells

- Two products approved by European Medicines Agency and European Commission (Aug 2018)

Yescarta

axicabtagene ciloleucel

About

Authorisation details

Product information

Assessment history

[Next tab »](#)

An overview of Yescarta and why it is authorised in the EU

Yescarta is a medicine for treating two types of blood cancer:

- ▶ diffuse large B-cell lymphoma (DLBCL);
- ▶ primary mediastinal large B-cell lymphoma (PMBCL).

Kymriah

tisagenlecleucel

About

Authorisation details

Product information

Assessment history

[Next tab »](#)

An overview of Kymriah and why it is authorised in the EU

Kymriah is a medicine for treating two types of blood cancer:

- ▶ B-cell acute lymphoblastic leukaemia (ALL), in children and young adults up to 25 years of age whose cancer did not respond to previous treatment, has come back two or more times, or has come back after a transplant of stem cells;
- ▶ Diffuse large B-cell lymphoma (DLBCL) in adults whose cancer has come back or did not respond after two or more previous treatments.



CAR T cell approval for reimbursement by UK HTA (NICE)

Kymriah

NICE National Institute for Health and Care Excellence

NICE Pathways | **NICE guidance** | Standards and indicators | Evidence services | Sign in

Search NICE...

Home > NICE Guidance > Conditions and diseases > Blood and immune system conditions > Blood and bone marrow cancer

Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma ID1166

In development [GID-TA10269] Expected publication date: TBC

Find a job | Don't sign in / Register | Search

ion | Sport | Culture | Lifestyle | More

UK edition

The Guardian

all UK politics Environment Education Society Science Tech Global development Cities Obituaries

NHS to treat young cancer patients with expensive 'game changer' drug

Chief executive to announce use of CAR-T therapy drug Kymriah, which costs £282,000 per patient

Advertisement

Spotify

Adios, ads.

Premium's free for the first 30 days. No interruptions.

PROVISIONAL



CAR T cell approval for reimbursement by UK HTA (NICE)

Kymriah

PharmaTimes
online

Search news, artik

NICE rejects Novartis' CAR-T Kymriah for adult lymphoma

NICE National Institute for Health and Care Excellence

NICE Pathways

NICE guidance

Star

[Share](#)

NICE encourages further discussions on Kymriah for adult lymphoma

CAR-T is too expensive to recommend as a treatment for adults with lymphoma, NICE says in draft guidance today (19 September).



CAR T cell approval for reimbursement by UK HTA (NICE)

Yescarta

NICE National Institute for Health and Care Excellence

28 August 2018

NICE
Pathways

NICE
guidance

Sta
anc

Feedback encouraged to allow use of life extending treatment on NHS for those with blood cancer

[Share](#)

CAR-T considered to be an exciting innovation which can cure some patients but very expensive

MailOnline



Children with leukaemia and adults with lymphoma face being DENIED 'cancer cure' as NHS officials and pharmaceutical bosses argue over pricing

The use of registries for CAR T cells

- European Bone Marrow Transplant (EBMT) registry currently under consideration to follow patients following CAR T cell treatments and compare the different therapies, especially considering potential toxicities
- Initial meeting in Feb 2018 to discuss the potential use of registries with multiple stakeholder resulting in a qualification recommendation (out to consultation)

Draft qualification opinion on Cellular therapy module of the European Society for Blood & Marrow Transplantation (EBMT) Registry

Agreed by Scientific Advice Working Party	17 May 2018
Adopted by CHMP for release for consultation	31 May 2018*
Start of public consultation	29 June 2018 [†]
End of consultation (deadline for comments)	21 August 2018 [‡]



CAT Workplan 2018

- Revision of the guideline on genetically modified cells
- Development of a guideline on requirements for ATMPs in clinical trials
- Development of guidance on comparability for ATMPs
- Reflection on the use of Registry data for the post-authorisation follow-up of ATMPs.
- Scientific and Regulatory considerations on gene editing technologies
- Addressing the Environmental Risk assessment of ATMPs containing genetically modified organisms (GMO) / genetically modified micro-organisms (GMM).



CAT Workplan 2018

- Revision of the guideline on genetically modified cells
- Development of a guideline on requirements for ATMPs in clinical trials
- Development of guidance on comparability for ATMPs
- Reflection on the use of Registry data for the post-authorisation follow-up of ATMPs.
- Scientific and Regulatory considerations on gene editing technologies
- Addressing the Environmental Risk assessment of ATMPs containing genetically modified organisms (GMO) / genetically modified micro-organisms (GMM).



Questions?

